A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer
Latest Information Update: 30 Nov 2022
At a glance
- Drugs Alpelisib (Primary) ; Fulvestrant (Primary) ; Goserelin; Leuprorelin; Leuprorelin
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms SAFIR PI3K
- 22 Nov 2022 Status changed from active, no longer recruiting to discontinued.
- 01 Oct 2022 Results comparing the efficacy of two trials (nos. NCT02299999 and NCT03386162) of maintenance treatment5 with a targeted therapy matched to genomic alteration published in the Nature
- 08 Mar 2022 Planned primary completion date changed from 1 Feb 2022 to 1 Oct 2022.